Advertisement

Loading...

Gemina Laboratories Ltd.

GLAB.CNCNQ
Healthcare
Biotechnology
$0.06
$0.00(0.00%)
Canadian Market opens in 17h 29m

Gemina Laboratories Ltd. (GLAB.CN) Stock Competitors & Peer Comparison

See (GLAB.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GLAB.CNCA$0.06+0.00%4.6M-1.50-CA$0.04N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$101.37+6.25%786.8M-36.73-CA$2.76N/A
EPRX.TOCA$10.04+7.96%360.8M-7.02-CA$1.43N/A
FRX.TOCA$8.33+0.00%236.4M-17.23-CA$0.48N/A
CYBN.NECA$6.72+11.07%162.2M-1.30-CA$5.17N/A
ONC.TOCA$1.42+2.16%142.3M-3.84-CA$0.37N/A
HBP.TOCA$1.86-4.12%142.1M-31.00-CA$0.06N/A
MSCL.TOCA$7.94-5.48%124M2.26CA$3.55N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GLAB.CN vs BLU.TO Comparison April 2026

GLAB.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAB.CN stands at 4.6M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, GLAB.CN is priced at CA$0.06, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAB.CN currently has a P/E ratio of -1.50, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, GLAB.CN's ROE is +0.62%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, GLAB.CN is less volatile compared to BLU.TO. This indicates potentially lower risk in terms of short-term price fluctuations for GLAB.CN.Check BLU.TO's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions